Patients with active Crohn’s disease who receive modified-release budesonide (Entocort EC) lose less bone mass than patients who receive the standard corticosteroid prednisolone, according to results of a randomised trial presented here October 22 at the 67th annual scientific meeting of the American College of Gastroenterology (ACG).
“Modified-release budesonide has a significant advantage in preservation of bone mass of the lumbar spine, compared with equipotent doses of prednisolone,” said Erik J. Schoon, MD, of the University Hospital Maastricht, in Maastricht, Netherlands.
Dr. Schoon reported results of a trial that included 272 patients with moderately active ileo-cecal Crohn’s disease who were not previously treated with oral steroids. Bone mass was investigated using a dual energy X-ray absorptiometry (DEXA) scan of the lumbar spine and a lateral X-ray of the thoracic and lumbar spine. Patients were followed for up to 24 months.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!